[ad_1]
Moderna has joined the world’s leading manufacturers of COVID-19 vaccines, investigating new Omicron variants and adapting shots to combat new strains that appear to have a high number of mutations and spread rapidly.
At the BBC’s Andrew Marr Show on Sunday, Modana’s chief medical officer, Paul Burton, may have a large availability of new represcription vaccines to combat newly identified variants early next year. Said there is.
Barton states that scientists and researchers are still “actually trying to solve” a new variant, whether it is more contagious, how serious its side effects are, and the vaccines currently available. We have established how we can contain and control it. The latter needs to be known within a few weeks after the researcher conducts the experiment in the laboratory.
“We need to know about the ability of current vaccines to provide protection in the coming weeks,” Burton said. “If we had to make a brand new vaccine, I think it would be early 2022 before it was actually available in large quantities,” Burton continued.
Burton added that Moderna mobilized “hundreds of people here in the United States and around the world” early Thursday after researchers identified a new variant in South Africa, and Moderna addressed such issues. He said he could “move very fast” to do so.
The new mutant contains multiple mutations, the Chief Medical Officer said, “at least 30 peplomers alone, 9 of which are known to be associated with antigenic escape,” “another 11 Individuals are predicted to be associated with antigenic escape. ” “
“You put them together [and] I think this is a virus of great concern, “he said, urging people to get vaccinated.
Modana Announced on Friday Testing high doses of current vaccines against Omicron variants.
“From the beginning, we have stated that it is essential to actively work on the evolution of the virus when trying to overcome the pandemic. There are concerns about mutations in the Omicron variant and we have to deal with this variant for a few days. We are moving as quickly as possible to implement our strategy, “said Stephen Bansel, CEO of Moderna.
“There are three lines of defense going on in parallel. We have already evaluated a high-dose booster (100 µg) for mRNA-1273. Next, we are studying two multivalent booster candidates in the clinic. Omicron mutation. Predicting mutations such as those appearing in the body, the data are expected in the coming weeks. Third, we are rapidly advancing the candidate Omicron-specific booster (mRNA-1273.529). “
Meanwhile, Pfizer and BioNTech have also begun investigating a variant Omicron, also known as B.1.1.529, ready to ship represcribed shots within 100 days if it is resistant to the current vaccine. Said that it was done.
“We understand the concerns of the experts and immediately began investigating variant B.1.1.529,” BioNTech said in a statement when asked for comment.
“We expect more data from laboratory tests within two weeks at the latest,” he added. “These data provide more information on whether B.1.1.529 may be an escape variant that may require vaccine adjustment if the variant spreads globally. Will provide. “
Elsewhere, Johnson & Johnson said he has begun testing the effectiveness of current shots against varieties of Omicron.
“We are carefully monitoring newly emerging COVID-19 virus strains with variations of the SARS-CoV-2 peaplomer and vaccine efficacy against the first new and rapidly spreading mutants detected in southern Africa. We have already tested sex, “J & J said. Statement to CNBC.
AstraZeneca is working with other vaccine makers to investigate new variants, “we are working in areas where the variants have been identified: Botswana and Eswatini,” the company said.
A new variant of the CCP (Chinese Communist Party) virus, commonly known as the new coronavirus, was announced last Thursday by South African Health Minister Joe Fara.
Since then, it has been detected in Botswana, Hong Kong, Israel, Europe, and the United Kingdom. Scientists say it has an unusual combination of mutations that may be able to avoid an immune response or make it more contagious.
follow
Katabella Roberts is a reporter currently based in Turkey. She focuses primarily on the United States and covers the news and business of The Epoch Times.
[ad_2]